Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905845 | 0.87 | HCRTR1 (0.46) | HCRTR1MEN1KMT2AIDO1GPR65 | |
| SCHEMBL6905283 | 0.83 | RAB9A (0.46) | HCRTR1MEN1KMT2AHCRTR2BRD4 | |
| SCHEMBL6905601 | 0.83 | ALDH1A1 (0.48) | HCRTR1MEN1KMT2AHCRTR2 | |
| SCHEMBL6905605 | 0.83 | ALDH1A1 (0.48) | HCRTR1MEN1KMT2AHCRTR2 | |
| SCHEMBL6905079 | 0.81 | HCRTR1 (0.43) | HCRTR1MEN1KMT2AIDO1GPR65 | |
| SCHEMBL6905076 | 0.81 | HCRTR1 (0.43) | HCRTR1MEN1KMT2AIDO1GPR65 | |
| SCHEMBL21067948 | 0.74 | HCRTR1 (0.40) | HCRTR1MEN1KMT2AUSP30HCRTR2 | |
| SCHEMBL1821517 | 0.72 | BACE1 (0.36) | MEN1KMT2AIDO1GPR65USP30 | |
| SCHEMBL14123637 | 0.72 | BACE1 (0.36) | MEN1KMT2AIDO1GPR65USP30 | |
| SCHEMBL14123658 | 0.72 | BACE1 (0.36) | MEN1KMT2AIDO1GPR65USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | HCRTR1 3146/4885MEN1 4674/4885KMT2A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.